Active ingredientRavuconazoleCat. No. P-R020-001CAS 182760-06-1Family · Pharmaceutical analytical standards
Ravuconazole
A broad-spectrum triazole antifungal studied around 2000; its oral prodrug, fosravuconazole, was approved in Japan in 2018 for onychomycosis, the fungal infection of the nails. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Fosravuconazole has also been tested against eumycetoma, a neglected tropical fungal infection: in 2023 a phase II study confirmed its efficacy as an oral treatment.
Go to the active ingredient →Active ingredientRavuconazoleCat. No. P-R020-001CAS 182760-06-1
Isotopically labelled(1S,2S)-Ravuconazole-d4Cat. No. P-R020-002
Isotopically labelledRavuconazole-d4Cat. No. P-R020-003CAS 1329499-27-5
Impurity(1R,2S)-RavuconazoleCat. No. P-R020-004
Impurity(1S,2R)-RavuconazoleCat. No. P-R020-005
Impurity(1S,2S)-RavuconazoleCat. No. P-R020-006No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.